Delving into the Latest Updates on Triclofos Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Triclofos, Triclofos sodium (JP17/USAN)

+ [3]

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication

Sleep Initiation and Maintenance Disorders

Inactive Indication

Coronary Disease

Originator Organization

Alfresa Pharma Corp.

Active Organization

Alfresa Pharma Corp.

Inactive Organization

Sanofi-Aventis U.S. LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (19 Nov 1964),

Sleep Initiation and Maintenance Disorders

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC2H4Cl3NaO4P

InChIKeyOFCLFJCRLNHIQE-UHFFFAOYSA-N

CAS Registry7246-20-0

View All Structures (2)

BACKGROUNDHead magnetic resonance imaging (MRI) is of critical importance in the diagnosis and management of neurodevelopmental disorders. However, the use of sedation in affected children can present a significant challenge.AIMSTo identify the factors associated with sedation and MRI failure in children with neurodevelopmental disorders undergoing head MRI with oral triclofos sodium or rectal chloral hydrate.METHODSThis retrospective study analyzed 215 MRI sessions of children with neurodevelopmental disorders from January 2020 to December 2021. Sedation was administered via oral triclofos sodium or rectal chloral hydrate. Multivariate logistic regression was used to determine the factors associated with sedation failure and MRI failure.RESULTSThe sedation failure rate was 38.1 % (82/215). Factors significantly associated with sedation failure were older age (odds ratio [OR] 1.59, 95 % confidence interval [CI] 1.30-1.95, p < 0.001) and stranger anxiety (OR 4.07, 95 % CI 1.95-8.49, p < 0.001). The age cut-off for increased sedation failure risk was 4.0 years (p < 0.01). The MRI failure rate was 21.9 % (47/215), associated with autism spectrum disorder (ASD) diagnosis (OR 19.00, 95 % CI 2.43-149.00, p < 0.01), stranger anxiety (OR 3.66, 95 % CI 1.62-8.24, p < 0.01), and place anxiety (OR 3.18, 95 % CI 1.33-7.57, p < 0.01).CONCLUSIONSOlder age and stranger anxiety are significant risk factors for sedation failure, while ASD diagnosis, stranger anxiety, and place anxiety increase MRI failure risk in children with neurodevelopmental disorders undergoing head MRI.

01 Apr 2025·Archives of Disease in Childhood

Randomised placebo-controlled trial of triclofos versus melatonin for sedating children undergoing sleep EEG

Article

Author: Jha, Ruchika ; Kohli, Sarvesh ; Ahmad, Faiz MH ; Devgan, Amit ; Badal, Sachendra ; Mohanan, Priyamol T ; Sondhi, Vishal ; Kurup, Arjun ; Ahmad, Faiz Mh ; Adhikari, Krishna Moorthi

ObjectiveTo determine the efficacy of addition of melatonin or triclofos to sleep deprivation as compared with sleep deprivation with placebo for conduct of successful sleep electroencephalogram (EEG) among children between 6 months and 12 years of age.Design, setting and Patients486 children aged between 6 months and 12 years who were uncooperative or referred for sleep EEG were enrolled for this double-blind, placebo-controlled randomised trial between 30 June 2022 and 31 March 2023.InterventionOn the day of sleep EEG, participants were sleep deprived by 25% of their regular sleep duration and then randomly assigned to receive either triclofos (50 mg/kg), melatonin (weight ≤15 kg=3 mg; weight >15 kg=6 mg) or placebo.OutcomePrimary outcome was the conduct of a successful sleep EEG.Results486 children were randomly assigned to intervention with triclofos (n=165), melatonin (n=161) or placebo (n=160). Sleep EEG success (p<0.001) with different interventions was: triclofos=145/165(88%); melatonin=123/161 (76%) and placebo=65/160 (41%). Sleep EEG’s success rate was better with triclofos than melatonin (OR=2.2; 95% CI 1.2 to 4.1) or placebo (OR=10.6; 95% CI 6.1 to 19.0). Melatonin was better than placebo in the rate of successful sleep EEG (OR=4.7; 95% CI 2.9 to 7.7). Beta artefacts were significantly more with triclofos (51/145) than melatonin (19/123) and placebo (12/65), but the readability of EEG was not impacted. Movement/unwanted arousal artefacts were significantly more with placebo (37/65) than with triclofos (37/145) and melatonin (34/123). Drug-related adverse events were comparable between triclofos and melatonin. Neither of the drugs was associated with any serious adverse events.ConclusionsBoth triclofos and melatonin are individually better than sleep deprivation alone for conducting successful sleep EEGs. Triclofos is significantly better than melatonin for conducting sleep EEGs, with no significant increase in adverse events.Trial registration numberCTRI/2022/05/042479; Clinical Trials Registry of India

01 Nov 2024·Microchimica Acta

Microfluidic-SERS sensing system based on dual signal amplification and aptamer for gastric cancer detection

Article

Author: Jiang, Fengjuan ; Yang, Yan ; Lu, Chengzhe ; Wang, Zhenguang ; Huang, Yong ; Chen, Miao ; Liu, Jia ; Zhu, Qunshan ; Li, Limao ; Wei, Wei ; Cao, Xiaowei ; Fu, Lei

Studies have found that matrix metalloproteinase-9 (MMP-9) and interleukin-6 (IL-6) play an important role in tumorigenesis. In order to detect MMP-9 and IL-6 concentrations with high sensitivity and specificity, an efficient microfluidic-SERS sensing system was prepared based on surface-enhanced Raman scattering (SERS). The aptamer recognition-release mechanism and the dual signal amplification strategy were applied in the sensing system. The sensor system was developed using two kinds of nanomaterials with excellent SERS properties, namely gold-coated iron tetroxide particles (Fe₃O₄@AuNPs) and gold nanocages (AuNCs). In addition, Fe₃O₄@AuNPs also has magnetic adsorption properties. In the sensing system, single-stranded DNA1 (ssDNA1) and aptamer were modified on Fe₃O₄@AuNPs. Single-stranded DNA2 (ssDNA2) and Raman tags were modified on AuNCs. When the target was present, the aptamer bound to the target and detached from the Fe₃O₄@AuNPs, and ssDNA2 bound to the exposed ssDNA1. At this time, the Fe₃O₄@AuNPs@AuNCs@SERS tag complex was formed, and the SERS signal was enhanced for the first time. Under the action of an external magnet on the microfluidic chip, the complex was magnetized and enriched. The SERS signal was enhanced for the second time. Due to the high affinity between the aptamer and the target object, the sensing system has a strong specificity. The double amplification of the SERS signal gave the system excellent sensitivity. The limit of detection (LOD) relative to MMP-9 and IL-6 were as low as 0.178 pg/mL and 0.165 pg/mL, respectively. The microfluidic-SERS sensing system has a feasible prospect in the early screening of gastric cancer.

100 Deals associated with Triclofos Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00388	Triclofos Sodium	N05CM07	DB06753

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	Japan	Alfresa Pharma Corp.	19 Nov 1964

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04270708 (Pubmed \| Paediatr Drugs)	Phase 4	Sedation	869	Triclofos Sodium	lsjctctfjy(cpcnzeblsh) = hwvqrmawuj vniiirxjzp (tkzjslvdrq ) View more	-	01 Oct 2019